Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;158(1):120-8.
doi: 10.1111/j.1365-2141.2012.09130.x. Epub 2012 Apr 26.

Success of allogeneic marrow transplantation for children with severe aplastic anaemia

Lauri M Burroughs  1 , Ann E Woolfrey, Barry E Storer, H Joachim Deeg, Mary E D Flowers, Paul J Martin, Paul A Carpenter, Kris Doney, Frederick R Appelbaum, Jean E Sanders, Rainer Storb
Affiliations

Success of allogeneic marrow transplantation for children with severe aplastic anaemia

Lauri M Burroughs et al. Br J Haematol. 2012 Jul.

Abstract

Allogeneic marrow transplantation offers curative therapy for children with severe aplastic anaemia (SAA). We report the outcomes of 148 children with SAA who received human leucocyte antigen (HLA)-matched related marrow grafts between 1971 and 2010. Patients were divided into three groups, reflecting changes in conditioning and graft-versus-host disease (GVHD) prophylaxis regimens that occurred over time. Patients in Group 1 were conditioned with cyclophosphamide (CY; 200 mg/kg) followed by 'long' (102 d) methotrexate (MTX). Patients in Groups 2 and 3 received CY alone (Group 2) or combined with anti-thymocyte globulin (Group 3) followed by 'short' (days 1, 3, 6, and 11) MTX and ciclosporin (until day 180). With a median follow-up of 25 years, the 5-year survivals were 66%, 95%, and 100% for Groups 1, 2, and 3, respectively (overall P < 0·0001). The 3-year estimates of graft rejection were 22%, 32%, and 7%, respectively. The probabilities of grades III-IV acute and 2-year chronic GVHD were 15%, 0%, and 3%, and 21%, 21%, and 10%, respectively. Advances in preparative and GVHD prophylaxis regimens, and supportive care during the past 40 years have led to improved outcomes for children with SAA. These results confirm the use of allogeneic marrow transplantation for children with SAA who have HLA-matched related donors.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Incidence of (A) graft rejection according to conditioning regimen and graft-versus-host disease (GVHD) prophylaxis over time in 148 children with severe aplastic anaemia (SAA) and (B) survival following second marrow transplantation for graft rejection according to the conditioning regimen and GVHD prophylaxis over time in 24 patients with SAA. ATG=anti-thymocyte globulin; CSP=ciclosporin; CY = cyclophosphamide; MTX=methotrexate.
Fig 2
Fig 2
Cumulative incidence of (A) Grade II acute graft-versus-host disease (GVHD) (B) Grade III–IV acute GVHD (C) and chronic GVHD in 148 children with severe aplastic anaemia. ATG=anti-thymocyte globulin; CSP=ciclosporin; CY = cyclophosphamide; MTX=methotrexate.
Fig 3
Fig 3
Survival (upper curves) and prevalence of chronic graft-versus-host disease (lower curves) among patients in (A) Group 1 (CY, MTX n=98) (B) Group 2 (CY, MTX + CSP n= 19) and (C) Group 3 (CY/ATG, MTX + CSP n=31) in 148 children with severe aplastic anaemia. ATG=anti-thymocyte globulin; CSP=ciclosporin; CY = cyclophosphamide; MTX=methotrexate.
Fig 4
Fig 4
Cumulative incidence of post-transplant cancer and cancer-related mortality in 148 children with severe aplastic anaemia.
Fig 5
Fig 5
Overall survival according to the conditioning regimen and graft-versus-host disease prophylaxis used in 148 children with severe aplastic anaemia. ATG=anti-thymocyte globulin; CSP=ciclosporin; CY = cyclophosphamide; MTX=methotrexate.
See this image and copyright information in PMC

References

    1. Appelbaum FR, Storb R, Ramberg RE, Shulman HM, Buckner CD, Clift RA, Deeg HJ, Fefer A, Sanders J, Stewart P, Sullivan K, Witherspoon R, Thomas ED. Allogeneic marrow transplantation in the treatment of preleukemia. Annals of Internal Medicine. 1984;100:689–693. - PubMed
    1. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, Gabbas A, Dufour C, Arcese W, Testi G, Broccia G, Carotenuto M, Coser P, Barbui T, Leoni P, Ferster A. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO) Blood. 2000;95:1931–1934. - PubMed
    1. Bean MA, Storb R, Graham T, Raff R, Sale GE, Schuening F, Appelbaum FR. Prevention of transfusion-induced sensitization to minor histocompatibility antigens on DLA-identical canine marrow grafts by gamma irradiation of marrow donor blood. Transplantation. 1991;52:956–960. - PubMed
    1. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063–4071. - PubMed
    1. Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, Bredeson CN, Eapen M, Horowitz MM. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007;109:4582–4585. - PMC - PubMed

Publication types